{"organizations": [], "uuid": "98387439f56370b5c0862d63af9b7e59a17ed445", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-oncocyte-announces-initial-results/brief-oncocyte-announces-initial-results-of-determavu-feasibility-on-new-platforms-idUSFWN1QQ10Q", "country": "US", "domain_rank": 408, "title": "BRIEF-Oncocyte Announces Initial Results Of Determavu™ Feasibility On New Platforms", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.884, "site_type": "news", "published": "2018-03-09T05:42:00.000+02:00", "replies_count": 0, "uuid": "98387439f56370b5c0862d63af9b7e59a17ed445"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-oncocyte-announces-initial-results/brief-oncocyte-announces-initial-results-of-determavu-feasibility-on-new-platforms-idUSFWN1QQ10Q", "ord_in_thread": 0, "title": "BRIEF-Oncocyte Announces Initial Results Of Determavu™ Feasibility On New Platforms", "locations": [], "entities": {"persons": [{"name": "oncocyte", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "oncocyte corp", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Oncocyte Corp:\n* ONCOCYTE ANNOUNCES INITIAL RESULTS OF DETERMAVU™ FEASIBILITY ON NEW PLATFORMS; ENHANCEMENTS MAY INCREASE LUNG CANCER DIAGNOSTIC TEST’S CLINICAL PERFORMANCE\n* ONCOCYTE CORP - CO IS ACTIVELY EVALUATING ALTERNATIVE ASSAY PLATFORMS FOR USE WITH MOLECULAR BIOLOGY DIAGNOSTIC TESTING​\n* ONCOCYTE CORP - ‍INITIAL RESULTS SHOW ILLUMINA PLATFORM COULD PROVIDE SUPPORT FOR CLINICAL DEVELOPMENT STUDIES NECESSARY FOR DETERMAVU​ COMMERCIALIZATION\n* ONCOCYTE CORP - ‍ONCOCYTE HAS ALSO IDENTIFIED WAYS THAT POTENTIALLY MAY ENHANCE LUNG CANCER SIGNAL IDENTIFIED BY DETERMAVU​\n* ONCOCYTE - CO EXTENDING EVALUATION OF COMMERCIAL MOLECULAR DIAGNOSTIC PLATFORMS BY DOING A FOLLOW-ON STUDY UTILIZING LARGER SET OF CLINICAL SAMPLES​ Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-09T05:42:00.000+02:00", "crawled": "2018-03-09T14:32:13.000+02:00", "highlightTitle": ""}